论文部分内容阅读
以30名健康志愿者作为参照,将39名中心性肥胖者作为治疗组干预十二周,观察治疗前后一般情况、胰岛素抵抗、C反应蛋白、相关炎症因子及纤溶系统变化。结果与对照组相比,肥胖人群胰岛素抵抗指数、C反应蛋白、游离脂肪酸、纤溶酶原激活物抑制物1均有升高,组织纤溶酶原激活物下降;治疗后,治疗组体重指数、腰围、腰臀比以及胰岛素抵抗指数、C反应蛋白、游离脂肪酸、纤溶酶原激活物抑制物1、组织纤溶酶原激活物均明显改善,差异有统计学意义。结论二甲双胍干预可明显降低代谢综合征肥胖高危人群肥胖和胰岛素抵抗指数,并在一定程度上改善炎症状态、纤溶系统功能,有助于减轻致动脉粥样硬化的危险性。
Thirty healthy volunteers were used as reference to treat 39 central obesity patients as treatment group for 12 weeks. The changes of general condition, insulin resistance, C-reactive protein, related inflammatory factors and fibrinolytic system were observed before and after treatment. Results Compared with the control group, the insulin resistance index, C-reactive protein, free fatty acid and plasminogen activator inhibitor 1 in obese subjects increased and the levels of plasminogen activator decreased in obese subjects. After treatment, the body mass index , Waist circumference, waist-to-hip ratio and insulin resistance index, C-reactive protein, free fatty acid, plasminogen activator inhibitor 1 and tissue plasminogen activator were significantly improved, the difference was statistically significant. Conclusion Metformin intervention can significantly reduce the obesity and insulin resistance index of high-risk obese people with metabolic syndrome, and to a certain extent, improve the function of inflammatory state and fibrinolytic system and help to reduce the risk of atherosclerosis.